BridgeBio Pharma announced on Mar. 12 that its small-molecule drug candidate BBP-418 showed significant improvement in a key disease biomarker during a Phase 3 study for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The company plans to submit an application to the U.S. Food and Drug Administration in the first half of this year, with analysts expecting a potential launch in late 2026 or early 2027.
The development is important because LGMD2I/R9 is a rare genetic disorder that weakens muscles and currently lacks disease-modifying treatments. BridgeBio’s findings could offer new hope for patients affected by this condition.
In the FORTIFY trial, BridgeBio enrolled 81 patients who received either BBP-418 or placebo. At three months, those treated with BBP-418 saw nearly double the levels of alpha dystroglycan (αDG), a biomarker linked to muscle stabilization, while placebo controls had almost no change. The company said these increases were sustained through twelve months and described them as “highly statistically significant.”
Analysts from Mizuho Securities said BridgeBio is “building on the potential of BBP-418 to rapidly improve biomarker levels and functional benefit” in LGMD2I/R9 patients. William Blair analysts noted that although FORTIFY was designed for accelerated approval using glycosylated αDG as a surrogate endpoint, the FDA has recommended aiming for traditional approval based on recent discussions with BridgeBio. “We believe [this] is indicative of the strength and consistency of both biomarker and functional efficacy data favoring BBP-418 treatment,” they said.
Jefferies analysts reported high confidence—over 90%—in full approval by late 2026 or early 2027, projecting at least $600 million in peak sales for BBP-418. Mizuho also observed that favorable effects began as early as three months into treatment, including improvements in clinical outcomes such as timed walking tests and pulmonary function.
The next steps include filing with the FDA and awaiting regulatory review. If approved, BBP-418 could become one of the first disease-modifying therapies available for LGMD2I/R9.
